Ausgabe 1/2012
Inhalt (15 Artikel)
Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?
Gary W. Middleton, Nicola E. Annels, Hardev S. Pandha
Immunization with N-propionyl polysialic acid–KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci
Lee M. Krug, Govind Ragupathi, Chandra Hood, Constantine George, Feng Hong, Ronglai Shen, Lauren Abrey, Harold J. Jennings, Mark G. Kris, Philip O. Livingston
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells
Stefanie J. Mandl, Ryan B. Rountree, Katie Dalpozzo, Lisa Do, John R. Lombardo, Peter L. Schoonmaker, Ulrike Dirmeier, Robin Steigerwald, Thierry Giffon, Reiner Laus, Alain Delcayre
HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response
Gaia Codolo, Matteo Fassan, Fabio Munari, Andrea Volpe, Piefrancesco Bassi, Massimo Rugge, Francesco Pagano, Mario Milco D’Elios, Marina de Bernard
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
Riccardo Danielli, Ruggero Ridolfi, Vanna Chiarion-Sileni, Paola Queirolo, Alessandro Testori, Ruth Plummer, Monica Boitano, Luana Calabrò, Costanza De Rossi, Anna Maria Di Giacomo, Pier Francesco Ferrucci, Laura Ridolfi, Maresa Altomonte, Clelia Miracco, Angelo Balestrazzi, Michele Maio
Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
Shangzi Wang, Igor A. Astsaturov, Catherine A. Bingham, Kenneth M. McCarthy, Margaret von Mehren, Wei Xu, R. Katherine Alpaugh, Yong Tang, Bruce A. Littlefield, Lynn D. Hawkins, Sally T. Ishizaka, Louis M. Weiner
CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
Kevin H. Kim, William W. Greenfield, Martin J. Cannon, Hannah N. Coleman, Horace J. Spencer, Mayumi Nakagawa
Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer
Yasuhiro Nihon-Yanagi, Kensuke Terai, Takeyoshi Murano, Takayuki Matsumoto, Shinichi Okazumi
Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer
Jian Ming, Guocheng Jiang, Qingfu Zhang, Xueshan Qiu, Enhua Wang
Widespread expressions of immunoglobulin superfamily proteins in cancer cells
Gregory Lee, Mingang Zhu, Bixia Ge, Suzanne Potzold
Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas
Jie Chen, Guosheng Li, Hong Meng, Yuchen Fan, Yonghong Song, Shurong Wang, Faliang Zhu, Chun Guo, Lining Zhang, Yongyu Shi
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines
Marijo Bilusic, James L. Gulley
A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens
Ursula J. E. Seidel, Claudia C. Oliveira, Margit H. Lampen, Thorbald van Hall
Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses
Michael Kalos
Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25–27, 2011, Mainz, Germany
Kathleen Hobohm, Torsten Seppmann, Cedrik M. Britten, Holger Hoff